Discovers and develops oral recombinant protein vaccines. Utilizes a proprietary oral vaccine platform for tablet-based delivery. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 304% a year over the last 4 years. Red columns mark years that ended in a loss.
The market pays 7.4× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
Against companies in its own sector, it looks cheaper than 97% of them.
Analysts' average target sits 303% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Clearly above the class average — a step short of the very top.
The price looks reasonable next to what the company earns.
Sales are growing strongly for its sector.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
An investor who bought at the very peak is down 94% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Over the last 4 years, sales grew about 304% a year on average.
There is $63.8M in the vault; even if every debt were paid off, $54.8M would remain.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
The stock sits at $0.50. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
Buyers haven’t stepped back in yet; the price hasn’t found its footing. Report-card grade: 41/100. For a turnaround signal, the stock first needs to close the gap with the market.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.